MPN

Myeloproliferative neoplasms (MPNs) are rare cancers and include diseases of the blood and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.

Advertisement
Advertisement
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Melissa BadamoMyelofibrosis | November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Melissa BadamoMyelofibrosis | November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Cailin ConnerMyelofibrosis | October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Cailin ConnerMyelofibrosis | October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Cailin ConnerMyelofibrosis | October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Cailin ConnerMyelofibrosis | October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Andrew MorenoMyelofibrosis | September 30, 2024
A real-world retrospective study evaluated transfusion dependent or nondependent patients at ruxolitinib initiation.
Andrew MorenoMyelofibrosis | September 27, 2024
Management of asymptomatic, clinically stable disease is not necessarily improved by implementing routine hemostasis tests.
Andrew MorenoMyelofibrosis | September 27, 2024
Investigational agent DISC-0974 produced anemia response independent of patient transfusion dependency or JAK inhibitor use.
Andrew MorenoMyelofibrosis | September 26, 2024
A study observed that addition of pelabresib to ruxolitinib led to bone marrow microenvironment improvement.
Prithviraj Bose, MDMyelofibrosis | September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Melissa BadamoMyelofibrosis | September 13, 2024
History of thrombotic events, hematocrit ≤0.45 L/L, and JAK2 p.V617F were identified as risk factors for progression.
Melissa BadamoMyelofibrosis | September 13, 2024
LOXL2 upregulation is associated with key inflammatory signaling pathways in primary myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
Treatment with selinexor reduced hepcidin and pro-inflammatory cytokines in patients with myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
The rates of baseline comorbidities and constitutional symptoms were higher in patients with anemia versus those without.
Rob DillardMyelofibrosis | September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Rob DillardMyelofibrosis | September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Rob DillardMyelofibrosis | September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Rob DillardMyelofibrosis | September 10, 2024
Patients with MF or ET with CALR or JAK2 mutations carried similar symptom burdens according to prospective data.
Julie GouldMyelofibrosis | September 9, 2024
The phase III MANIFEST-2 trial compared pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAKi-naive patients.
Julie GouldMyelofibrosis | September 6, 2024
The findings were from a retrospective study of patient data from the US Flatiron Health electronic health record database.
Julie GouldMyelofibrosis | September 9, 2024
A retrospective analysis covered two phase III trials of the JAK2 inhibitor in patients with and without monocytosis.
Julie GouldMyelofibrosis | September 6, 2024
A study evaluated progression according to hemoglobin levels, platelet counts, constitutional symptoms, and other markers.
Patrick DalyMyelofibrosis | August 6, 2024
CTLA-4 blockade increased the cytotoxic T-cell–mediated immune response against myelofibrosis cells in human xenografts.
Andrew MorenoMyelofibrosis | September 30, 2024
A Markov model has compared delayed with immediate performance of allogeneic HSCT following ruxolitinib failure in PMF.
Melissa BadamoMyelofibrosis | August 5, 2024
Using mass spectrometry-based proteomics, chemokine platelet factor 4 (PF4) was identified as a driver of myelofibrosis.
Melissa BadamoMyelofibrosis | July 24, 2024
New therapies, such as TP-3654, are currently being explored in combination studies.
Melissa BadamoMyelofibrosis | July 11, 2024
Three of four patients with myelofibrosis had objective responses at one year, and no dose-limiting toxicities were observed.
Melissa BadamoMyelofibrosis | September 30, 2024
No significant differences in HSCT were observed, suggesting haploidentical HSCT as an acceptable treatment approach.
Andrew MorenoMyelofibrosis | July 10, 2024
AI-driven quantitative analysis was compared with manual evaluation of bone marrow trephine slides in a phase II trial.
Melissa BadamoMyelofibrosis | July 1, 2024
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
Patrick DalyMyelofibrosis | June 17, 2024
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Patrick DalyMyelofibrosis | June 10, 2024
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
Patrick DalyMyelofibrosis | June 7, 2024
Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.
Leah SherwoodMyelofibrosis | May 22, 2024
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Melissa BadamoMyelofibrosis | April 30, 2024
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Melissa BadamoMyelofibrosis | April 30, 2024
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Melissa BadamoMyelofibrosis | April 29, 2024
Sotatercept monotherapy, and combined with ruxolitinib, is a safe and effective treatment for patients with PMF and anemia.
Blood Cancer TalksBlood Cancer Talks | April 18, 2024
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Melissa BadamoMyeloproliferative Neoplasms | March 29, 2024
Dr. Harrison discusses her current clinical research, building community with MPN Voice, and her journey into hematology.
Leah SherwoodMyelodysplastic Syndromes | March 28, 2024
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Patrick DalyMyelofibrosis | March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.